Growth returns to its historical trajectory, with valuation becoming the core issue in the next stage

Overview

L'Oréal's share price has been largely stagnant over the past twelve months, but operating fundamentals have strengthened. After a cyclical slowdown in the beauty industry in 2024–2025, the company's organic growth has reaccelerated over the past year, with particularly strong performance in the first half. Innovation-driven category expansion, broad-based market share gains, and improvement in the dermatological beauty business have reduced market concerns about long-term stagnation in the beauty industry. As the growth recovery is validated, the investment debate is shifting from whether fundamentals can recover to what valuation the market should pay for sustained organic growth above 6%.

Core views

First, the first half represents a clear growth inflection point, and the recovery is not driven by a single category but reflects broad-based improvement at the portfolio level. Second, improving category demand combined with accelerating market share gains should enable L'Oréal's medium-term growth to remain above the average level of the consumer staples industry. Third, near-term comparisons are becoming tougher and market expectations have already risen; Bernstein's forecast for the third quarter of 2026 is slightly below consensus, making the near-term trading opportunity more balanced. Fourth, foreign exchange and higher interest costs weigh on EPS forecasts, limiting the full transmission of improved sales growth into shareholder returns. Fifth, the core issue has now shifted to valuation, with limited potential upside implied by the target price.

Analysis framework

The report combines quarterly and annual organic sales growth, revenue, operating margin, and adjusted EPS forecasts, compares them with the prior model and Visible Alpha consensus expectations, and uses forward EV/EBITDA valuation to derive the target price. It also assesses the sustainability and risks of the recovery across business segments, regional growth, market share, cash flow, leverage, and capital returns.

Methodology notes

• Relative valuationEV/EBITDA

  Determines target valuation using the multiple of enterprise value relative to forward earnings before interest, tax, depreciation, and amortization.

  The report applies an 18.1x EV/EBITDA multiple to the future NTM+1 EBITDA forecast of EUR 11,788, deriving a target price of EUR 405.00 for OR.FP.

• Earnings forecastForecast revision analysis

  Compares new and old models to identify the impact of changes in operating assumptions, foreign exchange, and financing costs on earnings.

  The sales growth outlook remains strong, but foreign exchange and interest costs led the FY2026 adjusted EPS forecast to be reduced from EUR 14.11 to EUR 13.64.

• Expectation gap analysisConsensus comparison

  Compares the institution's forecasts with Visible Alpha consensus expectations to judge the likelihood of results exceeding or falling short of expectations.

  Bernstein's organic growth forecasts for 2026–2028 are all above consensus expectations, but its forecast for the third quarter of 2026 is 5.1%, slightly below consensus of 5.3%.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• L'Oréal (OR.FP)

  Core research subject

  Strengths

  Strong innovation capabilities, broad business portfolio, and continued market share gains; organic growth accelerated clearly in the first half, and the dermatological beauty business also improved.

  Weaknesses

  High valuation, foreign exchange and interest costs weighing on EPS, and near-term growth comparisons becoming tougher.

  Comparison

  Medium-term organic growth is expected to remain above the average level of the broader consumer staples industry, but the target price offers only about 4% upside.

  Risks

  Continued weakness in the Luxe business in China and the United States, growth in emerging markets and dermatological beauty falling short of expectations, rising interest rates, and major strategic changes.

Key data

• Rating and target priceMarket-Perform; EUR 405.00Relative to the closing price of EUR 388.50, the upside is about 4%.
• Organic sales growth forecasts for 2026–20286.4%, 6.0%, 6.3%Corresponding consensus expectations are 6.1%, 5.5%, and 5.6%, respectively.
• Organic growth forecasts for Q3 and Q4 20265.1%, 6.6%Q3 is slightly below the consensus expectation of 5.3%, while Q4 is above the consensus expectation of 4.9%.
• Revenue forecasts for 2026–2028EUR 47,206 million, EUR 50,315 million, EUR 53,484 million0.3%, 0.7%, and 1.1% above consensus expectations, respectively.
• Adjusted EPS forecasts2026 EUR 13.64; 2027 EUR 15.15Previous forecasts were EUR 14.11 and EUR 15.63, respectively, with the main downward drivers being foreign exchange and interest costs.
• Valuation metrics2026 EV/EBITDA 19.6x; adjusted P/E 28.5xThe target price uses an 18.1x forward NTM+1 EV/EBITDA multiple.
• Performance over the past 12 monthsAbsolute return 1.4%; underperformed EDME by 19.7 percentage pointsThe share price has significantly underperformed the European market benchmark, but the report believes fundamentals have improved.

Impact & implications

Broad-based acceleration in organic growth means L'Oréal has regained the scarcity value of growth above the average level of the consumer staples industry, helping restore market confidence in its long-term growth capability. If share gains and category recovery continue, the company may continue to command a higher valuation; however, the current target price implies limited returns, while near-term comparisons, foreign exchange, and interest costs pose constraints, making investment returns more dependent on earnings delivery and whether the valuation premium can be sustained.

Risks

• Interest rates rise faster or by more than expected, further increasing financing costs and weighing on earnings.
• A major change in company strategy undermines the current logic of innovation, category expansion, and market share gains.
• The Luxe business performs poorly over the long term in the U.S. and Chinese markets.
• Future growth areas such as emerging markets excluding China and dermatological beauty weaken.
• Adverse foreign exchange movements continue to erode the contribution of sales growth to EPS.
• Near-term comparisons are becoming tougher and market expectations have risen, making quarterly results more prone to expectation gaps.

What to watch

• Whether organic growth in the third quarter of 2026 can meet or exceed the consensus expectation of 5.3%.
• Whether the fourth quarter of 2026 can achieve the forecast organic growth of 6.6%.
• Consumer demand in China and the recovery progress of the Luxe business in the U.S. and China.
• The sustainability of growth in the dermatological beauty business and in emerging markets excluding China.
• Whether market share gains continue across major categories and regions.
• The impact of changes in foreign exchange, interest costs, and operating margin on EPS.
• Whether the company can support its current valuation premium with sustained organic growth above 6%.